Effects of Disease-modifying Anti-rheumatic Drugs on Sacroiliac MRI Score in Axial Spondyloarthritis: a Systematic Review and Meta-analysis

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2023 Dec 29

PMID 38158505

Authors

Aude Hansmaennel

Olivier Fakih

Aurelie Gerazime

Clement Prati

Mickael Chouk

Daniel Wendling

Frank Verhoeven

Affiliations

Soon will be listed here.

Abstract

Introduction: Sacroiliac bone marrow edema is an important factor in the diagnosis and management of axial spondyloarthritis (axSpA). The aim of this meta-analysis is to assess the effect of the different bDMARDs and tsDMARDs on the SPARCC score at 12-16 and 48-52 weeks.

Methods: A systematic review, performed on PubMed (including Medline), Cochrane (CENTRAL) and DOAJ databases, included randomized controlled studies evaluating the sacroiliac joint (SIJ) SPARCC score at 12-16 or 48-52 weeks in patients with axSpA meeting the ASAS 2009 criteria or the modified New York criteria. We included studies evaluating the effects of the different treatments on the SPARCC score of SIJ in axial spondyloarthritis in comparison to a control group.

Results: Eighteen studies were included in the meta-analysis. Nine studies evaluated the effect of TNFα inhibitors (TNFi), three for IL-17 inhibitors, and four for JAK inhibitors. At 12 and 16 weeks, SIJ SPARCC score was significantly improved by TNFi (WMD: - 3.29 [95% CI - 4.25; - 2, 34]), by IL-17 inhibitors (WMD: - 4.66 [95% CI - 6.22; - 3.09]), and by JAK inhibitors (JAKi) (WMD: - 3.06 [95% CI - 3.24; - 2.89]). There was no difference between the molecule subgroups. At 48-52 weeks, TNFα inhibitors reduced more SIJ SPARCC, but not significantly (WMD: - 2.26 [95% CI - 4.94; 0.42]), than placebo groups who began a TNFi treatment with delay.

Conclusion: Our meta-analysis shows a comparable improvement of the SIJ SPARCC score regarding TNFi, JAKi, and IL-17 inhibitors at three months and suggests the presence of an opportunity window. Key Points • Anti-TNF Ab, anti-IL17 Ab, and JAK inhibitor treatments reduce the sacroiliac joint SPARCC scores. • There is no difference between the different treatments in the reduction of the sacroiliac joint SPARCC score after 3 months in axial spondyloarthritis.

Citing Articles

Precision medicine in axial spondyloarthritis: current opportunities and future perspectives.

So J, Tam L Ther Adv Musculoskelet Dis. 2024; 16:1759720X241284869.

PMID: 39376594 PMC: 11457172. DOI: 10.1177/1759720X241284869.

References

Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J . The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009; 68(6):777-83. DOI: 10.1136/ard.2009.108233. View

van der Heijde D, Lie E, Kvien T, Sieper J, Van den Bosch F, Listing J . ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2008; 68(12):1811-8. DOI: 10.1136/ard.2008.100826. View

van der Heijde D, Braun J, Deodhar A, Baraliakos X, Landewe R, Richards H . Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. Rheumatology (Oxford). 2018; 58(3):388-400. PMC: 6381766. DOI: 10.1093/rheumatology/key128. View

Aouad K, Ziade N, Baraliakos X . Structural progression in axial spondyloarthritis. Joint Bone Spine. 2019; 87(2):131-136. DOI: 10.1016/j.jbspin.2019.04.006. View

Wendling D, Hecquet S, Fogel O, Letarouilly J, Verhoeven F, Pham T . 2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis. Joint Bone Spine. 2022; 89(3):105344. DOI: 10.1016/j.jbspin.2022.105344. View

Baraliakos X, Boehm H, Bahrami R, Samir A, Schett G, Luber M . What constitutes the fat signal detected by MRI in the spine of patients with ankylosing spondylitis? A prospective study based on biopsies obtained during planned spinal osteotomy to correct hyperkyphosis or spinal stenosis. Ann Rheum Dis. 2019; 78(9):1220-1225. DOI: 10.1136/annrheumdis-2018-214983. View

van der Heijde D, Sieper J, Maksymowych W, Lambert R, Chen S, Hojnik M . Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial. Arthritis Res Ther. 2018; 20(1):61. PMC: 5870399. DOI: 10.1186/s13075-018-1556-5. View

Herrada I, Devilliers H, Fayolle C, Attane G, Loffroy R, Verhoeven F . Diagnostic performance of sacroiliac and spinal MRI for the diagnosis of non-radiographic axial spondyloarthritis in patients with inflammatory back pain. Joint Bone Spine. 2020; 88(2):105106. DOI: 10.1016/j.jbspin.2020.105106. View

Maksymowych W, Lambert R, Ostergaard M, Pedersen S, Machado P, Weber U . MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. Ann Rheum Dis. 2019; 78(11):1550-1558. DOI: 10.1136/annrheumdis-2019-215589. View

10.

Maksymowych W, Inman R, Salonen D, Dhillon S, Williams M, Stone M . Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum. 2005; 53(5):703-9. DOI: 10.1002/art.21445. View

11.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339:b2535. PMC: 2714657. DOI: 10.1136/bmj.b2535. View

12.

van der Linden S, VALKENBURG H, Cats A . Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27(4):361-8. DOI: 10.1002/art.1780270401. View

13.

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

14.

Lambert R, Salonen D, Rahman P, Inman R, Wong R, Einstein S . Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2007; 56(12):4005-14. DOI: 10.1002/art.23044. View

15.

Hu Z, Xu M, Li Q, Lin Z, Liao Z, Cao S . Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis. Int J Rheum Dis. 2012; 15(4):358-65. DOI: 10.1111/j.1756-185X.2012.01734.x. View

16.

Sieper J, van der Heijde D, Dougados M, Mease P, Maksymowych W, Brown M . Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2012; 72(6):815-22. PMC: 3664374. DOI: 10.1136/annrheumdis-2012-201766. View

17.

Hededal P, Ostergaard M, Sorensen I, Loft A, Hindrup J, Thamsborg G . Development and Validation of MRI Sacroiliac Joint Scoring Methods for the Semiaxial Scan Plane Corresponding to the Berlin and SPARCC MRI Scoring Methods, and of a New Global MRI Sacroiliac Joint Method. J Rheumatol. 2017; 45(1):70-77. DOI: 10.3899/jrheum.161583. View

18.

Braun J, Baraliakos X, Hermann K, Landewe R, Machado P, Maksymowych W . Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. RMD Open. 2017; 3(1):e000430. PMC: 5566980. DOI: 10.1136/rmdopen-2017-000430. View

19.

Mok C, Li O, Chan K, Ho L, Hui P . Effect of golimumab and pamidronate on clinical efficacy and MRI inflammation in axial spondyloarthritis: a 48-week open randomized trial. Scand J Rheumatol. 2015; 44(6):480-6. DOI: 10.3109/03009742.2015.1038300. View

20.

Maksymowych W, Dougados M, van der Heijde D, Sieper J, Braun J, Citera G . Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. Ann Rheum Dis. 2015; 75(7):1328-35. PMC: 4941178. DOI: 10.1136/annrheumdis-2015-207596. View